What a pharmacopoeia does
A pharmacopoeia contains monographs and general texts covering identity, quality specifications and analytical procedures for pharmaceutical substances, excipients and finished products. WHO describes The International Pharmacopoeia as a source of recommended procedures and specifications that Member States may use for reference or adaptation.
A monograph can establish a public compendial standard. It does not by itself state that a company’s product has been tested, complies with the current monograph, is manufactured at a named site or is authorised for sale.
Match the monograph to the actual material or dosage form
Start with the exact substance or finished-product presentation and check the monograph title, edition and current status. A test for an active pharmaceutical ingredient is not automatically the test for a finished tablet, injection or oral liquid. General chapters may apply alongside a product monograph.
Where a monograph has been revised or omitted, use the current issuing source. WHO specifically notes that omitted International Pharmacopoeia monographs are no longer updated and users must ensure compliance with current rules and suitable reference substances.
Reference substances are part of the measurement system
WHO International Chemical Reference Substances support tests and assays described in The International Pharmacopoeia and can be used as primary standards or to calibrate secondary standards where the relevant procedure permits. Their identity, intended use, storage and validity need controlled handling.
A reference-substance catalogue entry does not establish the quality of a commercial batch. It supports an analytical procedure; the batch result still depends on sampling, method execution, instrument control, calculations and the applicable specification.
Do not assume pharmacopoeias are interchangeable
Different pharmacopoeias may harmonise selected texts, but equivalence should be established through the relevant recognised process, not assumed from similar test names. ICH Q4B describes a process for evaluating and recommending selected pharmacopoeial texts for use within ICH regions.
For a regulatory submission or release specification, identify which pharmacopoeia and edition the dossier or authority accepts and how any alternative method is justified.
How this applies to Luang Pharma
The public Luang Pharma portfolio does not claim compendial compliance for individual development records unless controlled evidence is available for the exact product. A generic external monograph can explain the type of standard that may be relevant, but it cannot be used to fill missing Luang specifications or analytical results.
Professional enquiries should request the applicable specification, test methods, pharmacopoeial references and controlled product documents for the exact proposed presentation.
Sources and further reading
- WHO: The International Pharmacopoeia, 11th edition overview
- WHO International Chemical Reference Substances
- WHO Index of World Pharmacopoeias and Pharmacopoeial Authorities (2025)
- ICH Q4B evaluation and recommendation of pharmacopoeial texts
Source links and editorial scope checked 11 September 2026. External sources remain attributable to their issuers and do not establish Luang Pharma product or facility status.